Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | SLC22A1 | O15245 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.65 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.62 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.62 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.62 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 6/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.62 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | G6PD | P11413 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21807739 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL4925553 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL3181285 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL6655376 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL6448963 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL6575174 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL6573913 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL6575143 | 1.00 | SHBG (0.65) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| Propionic Acid SCHEMBL634971 | 0.91 | PDK1 (0.60) | SHBGSERPINA6SLC22A1ALDH1A1THRB | |
| SCHEMBL4321179 | 0.87 | SHBG (0.50) | SHBGSERPINA6SLC22A1ALDH1A1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 416 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| EP-3808348-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY (PML) | Biogen MA Inc. (US) | 2021-04-21 | — | — | EP | claimed |
| EP-3612223-A1 | Treating Male Senescence | National Institute Of Biological Sciences, Beijing (CN) | 2020-02-26 | — | — | EP | claimed |
| US-20200046714-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2020-02-13 | — | — | US | claimed |
| WO-2018192416-A1 | Treating Male Senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-10-25 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| CN-101883556-B | Transdermal delivery system for hormones and steroids | ACRUX DDS PTY LTD | 2013-05-29 | — | — | CN | claimed |
| US-8110565-B2 | Of the ACE inhibitor ramipril; controlling the melting point by mixing with the free acid with the ramipril ethyl or methyl ester prodrug and a pressure sensitive adhesive carrier; improved pharmacokinetics; sustained release | NOVEN PHARMACEUTICALS, INC. (US) | 2012-02-07 | — | — | US | claimed |
| EP-1406633-B1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMA (US) | 2011-10-05 | — | — | EP | claimed |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | ROBERTS WILLIAM J (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003002058-A2 | BONE ANABOLIC COMPOUNDS AND METHODS OF USE | ANABONIX, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| WO-2002102390-A1 | ENHANCED DRUG DELIVERY IN TRANSDERMAL SYSTEMS | NOVEN PHARMACEUTICALS, INC. (US) | 2002-12-27 | — | — | WO | claimed |
| US-20020183532-A1 | Bioavailable prodrugs of androgenic steroids and related method | BIOTEST LABORATORIES, LLC | 2002-12-05 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6117429-A | ANTIDIHYDROTESTOSTERONE ZINC COMPOUND | WEIDER NUTRITION INTERNATIONAL, INC (US) | 2000-09-12 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-1999007381-A1 | COMPOSITIONS AND TREATMENTS TO REDUCE SIDE EFFECTS OF ADMINISTRATION OF ANDROGENIC TESTOSTERONE PRECURSORS | WEIDER NUTRITION INTERNATIONAL, INC. (US) | 1999-02-18 | — | — | WO | claimed |
| EP-0496520-A1 | Novel bone acting agents | MERCK & CO. INC. (US) | 1992-07-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | SHBG 293/4885SERPINA6 4024/4885SLC22A1 4608/4885 |
| US-20200046714-A1 | Treating Male Senescence | RIPK3, RIPK1, MLKL | SHBG 293/4885SERPINA6 4024/4885SLC22A1 4608/4885 |
| US-20030134828-A1 | Composition and method for increasing in vivo androgen concentration | SHBG, CYP21A2, CYP19A1 | SHBG 1/4885SERPINA6 108/4885SLC22A1 768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.